Investigating a protein's role in amyloid plaque formation in Alzheimer's disease
FAM222A and amyloid plaque deposition in Alzheimer's Disease
This study is looking at how a protein called Aggregatin helps form the sticky plaques in the brains of people with Alzheimer's disease, and by understanding this process better, researchers hope to find new ways to slow down or prevent the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-10875761 on NIH RePORTER |
What this research studies
This research focuses on understanding how a protein called Aggregatin contributes to the formation of amyloid plaques in Alzheimer's disease (AD). Researchers will explore the interactions between Aggregatin and amyloid beta (Aβ), a key player in AD pathology, to uncover the mechanisms behind plaque accumulation. By studying both human brain samples and transgenic mouse models, the team aims to identify potential targets for new treatments that could slow or prevent the progression of AD. Patients may benefit from insights gained into the biological processes that lead to dementia.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it due to genetic or age-related factors.
Not a fit: Patients with non-neurodegenerative forms of dementia or those without any cognitive impairment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that target amyloid plaque formation, potentially slowing the progression of Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in targeting amyloid beta in Alzheimer's disease, suggesting that this approach may yield valuable insights and potential breakthroughs.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Wang, Xinglong — University of Arizona
- Study coordinator: Wang, Xinglong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.